Beijing Beilu Pharmaceutical Co Ltd
SZSE:300016
Relative Value
The Relative Value of one Beijing Beilu Pharmaceutical Co Ltd stock under the Base Case scenario is 7.08 CNY. Compared to the current market price of 10.24 CNY, Beijing Beilu Pharmaceutical Co Ltd is Overvalued by 31%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Multiples Across Competitors
Competitors Multiples
Beijing Beilu Pharmaceutical Co Ltd Competitors
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CN |
B
|
Beijing Beilu Pharmaceutical Co Ltd
SZSE:300016
|
5.9B CNY | 5.1 | 172.4 | 106 | 106 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
960.1B USD | 14.7 | 46.5 | 31.4 | 33.4 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
579.4B USD | 6.2 | 21.6 | 15 | 18.4 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
281.2B CHF | 4.6 | 29.9 | 12.6 | 14.8 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
228.3B GBP | 5.5 | 33.7 | 16 | 23.5 | |
| CH |
|
Novartis AG
SIX:NOVN
|
235.6B CHF | 5.4 | 21.7 | 13.4 | 17.2 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
295.4B USD | 4.5 | 16.2 | 10.1 | 11.8 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD | 94 | -74.6 | 333.1 | 835.4 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.4T DKK | 4.4 | 13.2 | 9.7 | 11.4 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
158B USD | 2.5 | 20.3 | 7.5 | 10.1 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
122.2B USD | 2.5 | 17.3 | 6.8 | 8.7 |